Naoko Iwamoto1, Tomoyuki Aruga2, Shinichiro Horiguchi3, Chiaki Saita2, Mai Onishi2, Risa Goto2, Toshiyuki Ishiba2, Yayoi Honda2, Hiromi Miyamoto2, Katsumasa Kuroi4. 1. Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. naoko-iwamoto@cick.jp. 2. Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. 3. Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. 4. Department of Breast Surgery, Tokyo Metropolitan Health and Hospitals Corporation Ebara Hospital, 4-5-10 Higashiyukigaya, Ota-ku, Tokyo, 146-0065, Japan.
Abstract
PURPOSE: The present study aimed to identify the predictive factors of an axillary pathological complete response (Ax-pCR) in patients with node-positive breast cancer who underwent neoadjuvant chemotherapy (NAC). METHODS: The present study included 219 patients who underwent NAC followed by curative surgery, including axillary lymph node dissection (ALND), for 221 breast cancers between January 2010 and April 2018. All patients were clinically and/or pathologically confirmed to be node-positive at the initial diagnosis. The predictive factors of Ax-pCR were analyzed using a chi-square test and multivariate logistic regression models. RESULTS: Ninety-five patients (43%) achieved Ax-pCR after NAC. The odds of achieving Ax-pCR were significantly improved when tumors were high grade (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.00-4.84), estrogen receptor (ER) negative (OR 2.65 95% CI 1.23-5.70), ycN0 on ultrasound (US) imaging (OR 3.89, 95% CI 1.90-7.97), and showed a clinical complete response (CR) at the primary site after NAC (OR 4.22, 95% CI 1.59-11.27). CONCLUSIONS: Ax-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others. Among these patients, those with initially cN1/N2 might be good candidates for a deescalated treatment strategy after NAC.
PURPOSE: The present study aimed to identify the predictive factors of an axillary pathological complete response (Ax-pCR) in patients with node-positive breast cancer who underwent neoadjuvant chemotherapy (NAC). METHODS: The present study included 219 patients who underwent NAC followed by curative surgery, including axillary lymph node dissection (ALND), for 221 breast cancers between January 2010 and April 2018. All patients were clinically and/or pathologically confirmed to be node-positive at the initial diagnosis. The predictive factors of Ax-pCR were analyzed using a chi-square test and multivariate logistic regression models. RESULTS: Ninety-five patients (43%) achieved Ax-pCR after NAC. The odds of achieving Ax-pCR were significantly improved when tumors were high grade (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.00-4.84), estrogen receptor (ER) negative (OR 2.65 95% CI 1.23-5.70), ycN0 on ultrasound (US) imaging (OR 3.89, 95% CI 1.90-7.97), and showed a clinical complete response (CR) at the primary site after NAC (OR 4.22, 95% CI 1.59-11.27). CONCLUSIONS: Ax-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others. Among these patients, those with initially cN1/N2 might be good candidates for a deescalated treatment strategy after NAC.
Entities:
Keywords:
Axillary lymph node dissection; Breast cancer; Neoadjuvant; Node-positive
Authors: Bryan T Hennessy; Gabriel N Hortobagyi; Roman Rouzier; Henry Kuerer; Nour Sneige; Aman U Buzdar; Shu Wan Kau; Bruno Fornage; Aysegul Sahin; Kristine Broglio; S Eva Singletary; Vicente Valero Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Lori F Gentile; George Plitas; Emily C Zabor; Michelle Stempel; Monica Morrow; Andrea V Barrio Journal: Ann Surg Oncol Date: 2017-09-15 Impact factor: 5.344
Authors: Brittany L Murphy; Tanya L Hoskin; Courtney Day N Heins; Elizabeth B Habermann; Judy C Boughey Journal: Ann Surg Oncol Date: 2017-05-08 Impact factor: 5.344
Authors: Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Abigail S Caudle; Wei T Yang; Elizabeth A Mittendorf; Daliah M Black; Rosa Hwang; Brian Hobbs; Kelly K Hunt; Savitri Krishnamurthy; Henry M Kuerer Journal: JAMA Surg Date: 2015-02 Impact factor: 14.766
Authors: Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi Journal: Lancet Oncol Date: 2013-03-11 Impact factor: 41.316
Authors: Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt Journal: JAMA Date: 2013-10-09 Impact factor: 56.272